Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04733274 · ClinicalTrials.gov registry record
Patient and Healthcare Professional Views on Genetic/Genomic Information and Testing
A clinical trial of Kallmann Syndrome and Hypogonadism, Hypogonadotropic, sponsored by Boston College.
- Active
- Registry status
- 227
- Enrollment target
- 2
- Study locations
NCT04733274: Active study of Kallmann Syndrome and Hypogonadism, Hypogonadotropic, sponsored by Boston College.
NCT04733274 is a study of Kallmann Syndrome and Hypogonadism, Hypogonadotropic that is active but no longer recruiting, run by Boston College. The registered enrollment target is 227 participants. The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04733274, a study of Kallmann Syndrome and Hypogonadism, Hypogonadotropic, is active but no longer recruiting, sponsored by Boston College.
- ACTIVE NOT RECRUITING
- Registry status
- 227 participants
- Enrollment target
- 2
- Study locations
Study Summary
Technologic advances (i.e. next generation sequencing technologies and novel bioinformatics approaches) have been drivers of scientific discovery and have deepened our understanding of the genetics and genomics of health and disease. In parallel, the falling cost of sequencing has led to screening moving from specialty clinics into the primary care setting. However, our ability to help patients and families understand these technologies and related genetic health literacy issues lag behind. These factors pose a number of questions and challenges for clinicians including: how can we best present complex genetic/genomic information to patients to ensure that patients understand the information and can make informed decisions? What are the specific information and support needs of patients and families to be able to make decisions that are in line with their values? In collaboration with investigators from the Harvard Reproductive Endocrine Sciences Center at the Massachusetts General Hospital, this project broadly aims to examine patient understanding and factors affecting decisions surrounding genetic testing. Using the paradigm of a rare genetic disorder (isolated gonadotropin releasing hormone \[GnRH\] deficiency - hypogonadotropic hypogonadism/Kallmann syndrome \[HH/KS\]) we will examine the views and perspectives of patients and healthcare professionals alike regarding genetic/genomic information and testing with the intention of identifying patient-centered responses to these unmet needs and challenges.
Primary Outcome
Patient Education Materials Assessment Tool (PEMAT): higher scores indicate materials that are more readily understood and actionable by patients
Conditions Studied
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Boston College - Chestnut Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2018-03-22 |
| Est. Completion | 2025-12-31 |
What the registry record for NCT04733274 still lists
NCT04733274 is an observational study that tracks outcomes without assigning an intervention. The registered 227 participants enrollment target is mid-sized for trials with a published cap.
The record links to 2 conditions, with Kallmann Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT04733274 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04733274 about?
NCT04733274 is a clinical study titled "Patient and Healthcare Professional Views on Genetic/Genomic Information and Testing". Technologic advances (i.e. next generation sequencing technologies and novel bioinformatics approaches) have been drivers of scientific discovery and have deepened our understanding of the genetics and genomics of health and disease. In parallel, the falling cost of sequencing has led to screening m...
What is the current status of trial NCT04733274?
This trial is currently active not recruiting. The enrollment target is 227 participants. The study started on 2018-03-22. Estimated completion is 2025-12-31.
What conditions does trial NCT04733274 study?
This clinical trial studies the following conditions: Kallmann Syndrome, Hypogonadism, Hypogonadotropic.
Who is sponsoring clinical trial NCT04733274?
This trial is sponsored by Boston College, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04733274 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kallmann Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04751409 · 227 participants · Phase 2
Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities
- NCT05742360 · 227 participants
Effect of CPAP on Blood Pressure in Excessively Sleepy Obstructive Sleep Apnea Subtype
- NCT05890352 · 227 participants · Phase 2
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI